Many recent studies have provided convincing evidence of a strong correlation between the activated HIF-1 pathway and tumor metastasis, angiogenesis, and poor patient prognosis as well as tumor resistance therapy [17–19]. This evidence concerns the gene SETD2 and neoplasm.